Evaluation of antioxidant status and lipid peroxidation in dogs with myxomatous mitral valve degeneration stage B1
- PMID: 37745214
- PMCID: PMC10512023
- DOI: 10.3389/fvets.2023.1203480
Evaluation of antioxidant status and lipid peroxidation in dogs with myxomatous mitral valve degeneration stage B1
Abstract
Myxomatous mitral valve degeneration (MMVD) is the most common naturally occurring heart disease in dogs. There is a lack of data on antioxidant status and oxidative damage in dogs with MMVD stage B1 according to the American College of Veterinary Internal Medicine (ACVIM B1). The aim of this study was to investigate antioxidant status (plasma vitamin E, lipid-standardized vitamin E (LS-VitE), antioxidant capacity of lipid-(ACL) and water-soluble antioxidants, whole blood glutathione peroxidase and erythrocyte superoxide dismutase), and lipid peroxidation [malondialdehyde (MDA)] in dogs with MMVD ACVIM B1. Serum cholesterol and triglyceride concentrations were measured to calculate LS-VitE. Fourteen dogs with MMVD ACVIM B1 and 12 control dogs were included in the study. Dogs with MMVD had significantly higher vitamin E, ACL, MDA, and cholesterol concentrations and significantly higher LS-VitE values than control dogs. No significant correlations between MDA and antioxidant parameters were determined in either group. In conclusion, oxidative damage to lipids is already present and the antioxidant status is altered but not depleted in dogs with MMVD ACVIM B1. The antioxidant response to increased oxidative damage consists mainly of the activation of fat-soluble antioxidants. Further research is needed to evaluate the efficacy and targets of early antioxidant supplementation to prevent or ameliorate oxidative stress and mitigate disease progression in dogs with early-stage MMVD.
Keywords: antioxidant status; dog; lipid peroxidation; myxomatous mitral valve degeneration; oxidative stress.
Copyright © 2023 Tomsič, Domanjko Petrič, Nemec, Pirman, Rezar, Seliškar, Vovk and Nemec Svete.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Similar articles
-
Antioxidant capacity of lipid- and water-soluble antioxidants in dogs with subclinical myxomatous mitral valve degeneration anaesthetised with propofol or sevoflurane.BMC Vet Res. 2020 Aug 24;16(1):305. doi: 10.1186/s12917-020-02529-7. BMC Vet Res. 2020. PMID: 32831105 Free PMC article.
-
Diagnostic value of atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP) and their correlation with lipoproteins in dogs with myxomatous mitral valve disease.BMC Vet Res. 2022 Dec 23;18(1):448. doi: 10.1186/s12917-022-03548-2. BMC Vet Res. 2022. PMID: 36564735 Free PMC article.
-
Markers of Oxidative Stress in Dogs with Myxomatous Mitral Valve Disease are Influenced by Sex, Neuter Status, and Serum Cholesterol Concentration.J Vet Intern Med. 2017 Mar;31(2):295-302. doi: 10.1111/jvim.14647. Epub 2017 Jan 29. J Vet Intern Med. 2017. PMID: 28132441 Free PMC article.
-
Pharmacologic management of myxomatous mitral valve disease in dogs.J Vet Cardiol. 2012 Mar;14(1):165-84. doi: 10.1016/j.jvc.2012.02.002. Epub 2012 Mar 3. J Vet Cardiol. 2012. PMID: 22386553 Review.
-
Comparative pathology of human and canine myxomatous mitral valve degeneration: 5HT and TGF-β mechanisms.Cardiovasc Pathol. 2020 May-Jun;46:107196. doi: 10.1016/j.carpath.2019.107196. Epub 2020 Jan 7. Cardiovasc Pathol. 2020. PMID: 32006823 Free PMC article. Review.
Cited by
-
Involvement of TGF-β, mTOR, and inflammatory mediators in aging alterations during myxomatous mitral valve disease in a canine model.Geroscience. 2025 Jan 27. doi: 10.1007/s11357-025-01520-0. Online ahead of print. Geroscience. 2025. PMID: 39865135
References
-
- Petrič AD. Myxomatous mitral valve disease in dogs—an update and perspectives. Maced Vet Rev. (2015) 38:13–20. doi: 10.14432/j.macvetrev.2014.11.026 - DOI
-
- Orozco SC, Olivera-Angel M, Vargas-Pinto P. Insights on the canine mitral valve in the course of myxomatous mitral valve disease. CES Med Vet Zootecn. (2019) 14:40–56. doi: 10.21615/cesmvz.14.1.4 - DOI
LinkOut - more resources
Full Text Sources